—
C+
C+ The full Closelook — membership. Open the C+ overview

UCB SA (UCB.BR) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — UCB SA

UCB.BR in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
UCB is a biopharmaceutical company based in Brussels that develops medicines for neurology and immunology conditions. Its portfolio includes treatments for epilepsy, Parkinson's disease, psoriasis and related immune disorders, alongside allergy remedies and newer drugs aimed at rare neurological and autoimmune diseases. The company also carries out contract manufacturing work alongside its own drug development.
Where it sits in the stack
UCB does not hold a seat in Rubin or in Halo, the diary's build-out indices, since its business sits outside the AI hardware and software chain. It belongs instead to the Healthcare sleeve of our wider universe, grouped with other scored pharmaceutical and biotechnology names rather than with any layer of the compute stack.
Who it is priced against
Closelook's peer group places UCB with other scored healthcare names, including Argen-X, Eli Lilly, Medpace, BeiGene, Fisher & Paykel Healthcare, Globus Medical and Regeneron, chosen because they share the sector. A comparison the market often draws outside that list is with Novartis.
Why Closelook tracks it
UCB carries a Closelook score with quality as its strongest module and momentum as its weakest; it holds no seat in Rubin or Halo and the diary records no quotes or index mentions for it.
What the diary watches
Whether the weak momentum reading persists or turns, and whether the pipeline names now in development change the growth module that currently sits well ahead of the score's other parts.

UCB SA (UCB.BR) trades on the BR exchange in Belgium, classified under Healthcare.

The Closelook company score reads 60/100 composite (momentum 17, quality 70, valuation 58) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for UCB.BR, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against UCB.BR on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 0.49%, annual · buybacks 121 m EUR in FY2025

Dividends and capital return

What UCB.BR pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 1.03 EUR per share · a 0.49% yield on the 2026-09-18 close 1 distribution, paid once a year 2026-09-18
  • Change on the year +5.5% against the prior twelve months prior twelve months 0.97 EUR per share
  • Last distribution 1.03 EUR per share as the price series records it, within days of the ex-date 2026-05-04
  • By calendar year 2025: 0.97 EUR (partial) · 2026: 1.03 EUR to date first distribution recorded in the three-year window: 2025-04-25
  • Dividends paid, FY2025 264 m EUR 18% of earnings
  • Buybacks, FY2025 121 m EUR 0.3% of today's market value
  • Share count −2.6% in FY2025
  • Capital returned 385 m EUR · 20% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in Europe: +3.0% week · −4.5% month · −2.1% quarter · −5.0% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is UCB SA (UCB.BR)?

UCB SA trades as UCB.BR on the BR exchange (Belgium) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is UCB.BR in a Closelook index?

Not currently — UCB SA is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is UCB SA's Closelook composite score?

60 out of 100, with momentum 17, quality 70 and valuation 58 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does UCB.BR trade against its moving averages?

Downtrend stack: Trades -6.8% vs the 50-day and -15% vs the 200-day average, 27.8% below the 52-week high and +9.3% off the 52-week low; a death cross printed 29 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does UCB SA do?

UCB is a biopharmaceutical company based in Brussels that develops medicines for neurology and immunology conditions. Its portfolio includes treatments for epilepsy, Parkinson's disease, psoriasis and related immune disorders, alongside allergy remedies and newer drugs aimed at rare neurological and autoimmune diseases. The company also carries out contract manufacturing work alongside its own drug development. Closelook's peer group places UCB with other scored healthcare names, including Argen-X, Eli Lilly, Medpace, BeiGene, Fisher & Paykel Healthcare, Globus Medical and Regeneron, chosen because they share the sector. A comparison the market often draws outside that list is with Novartis.

Where does UCB SA sit in the AI build-out?

UCB does not hold a seat in Rubin or in Halo, the diary's build-out indices, since its business sits outside the AI hardware and software chain. It belongs instead to the Healthcare sleeve of our wider universe, grouped with other scored pharmaceutical and biotechnology names rather than with any layer of the compute stack. UCB carries a Closelook score with quality as its strongest module and momentum as its weakest; it holds no seat in Rubin or Halo and the diary records no quotes or index mentions for it.

Does UCB SA pay a dividend?

UCB SA has paid 1.03 EUR per share over the last twelve months, paid once a year, a trailing yield of 0.49% on the 2026-09-18 close; the last distribution recorded in the price series was 1.03 EUR on 2026-05-04. In fiscal 2025 the company paid 264 m EUR in dividends and bought back 121 m EUR of its own shares, 20% of that year’s free cash flow. The share count fell 2.6% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for UCB.BR, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.